AMGN
Amgen Inc
Company · XNAS · US · USD
Market price
$401.63
+$48.84 (+13.85%) · 3 months
| Date and time | Price |
|---|---|
| Jun 25, 2026 | $352.79 |
| Jun 26, 2026 | $358.11 |
| Jun 29, 2026 | $360.55 |
| Jun 30, 2026 | $362.06 |
| Jul 1, 2026 | $361.12 |
| Jul 2, 2026 | $374.06 |
| Jul 6, 2026 | $366.44 |
| Jul 7, 2026 | $367.96 |
| Jul 8, 2026 | $368.03 |
| Jul 9, 2026 | $363.61 |
| Jul 10, 2026 | $363.59 |
| Jul 13, 2026 | $360.45 |
| Jul 14, 2026 | $355.29 |
| Jul 15, 2026 | $358.27 |
| Jul 16, 2026 | $371.59 |
| Jul 17, 2026 | $366.20 |
| Jul 20, 2026 | $364.17 |
| Jul 21, 2026 | $366.23 |
| Jul 22, 2026 | $366.22 |
| Jul 23, 2026 | $371.52 |
| Jul 24, 2026 | $375.70 |
| Jul 27, 2026 | $376.26 |
| Jul 28, 2026 | $393.01 |
| Jul 29, 2026 | $387.69 |
| Jul 30, 2026 | $387.78 |
| Jul 31, 2026 | $385.18 |
| Aug 3, 2026 | $378.87 |
| Aug 4, 2026 | $390.38 |
| Aug 5, 2026 | $407.70 |
| Aug 6, 2026 | $404.85 |
| Aug 7, 2026 | $410.91 |
| Aug 10, 2026 | $417.20 |
| Aug 11, 2026 | $414.32 |
| Aug 12, 2026 | $416.18 |
| Aug 13, 2026 | $417.84 |
| Aug 14, 2026 | $415.14 |
| Aug 17, 2026 | $419.38 |
| Aug 18, 2026 | $425.30 |
| Aug 19, 2026 | $442.43 |
| Aug 20, 2026 | $433.82 |
| Aug 21, 2026 | $439.40 |
| Aug 24, 2026 | $443.84 |
| Aug 25, 2026 | $442.34 |
| Aug 26, 2026 | $440.34 |
| Aug 27, 2026 | $436.98 |
| Aug 28, 2026 | $432.42 |
| Aug 31, 2026 | $429.88 |
| Sep 1, 2026 | $438.12 |
| Sep 2, 2026 | $442.84 |
| Sep 3, 2026 | $444.12 |
| Sep 4, 2026 | $437.23 |
| Sep 8, 2026 | $393.17 |
| Sep 9, 2026 | $391.27 |
| Sep 10, 2026 | $382.47 |
| Sep 11, 2026 | $377.35 |
| Sep 14, 2026 | $381.50 |
| Sep 15, 2026 | $375.65 |
| Sep 16, 2026 | $376.35 |
| Sep 17, 2026 | $379.78 |
| Sep 18, 2026 | $385.65 |
| Sep 21, 2026 | $393.16 |
| Sep 22, 2026 | $410.24 |
| Sep 23, 2026 | $406.09 |
| Sep 24, 2026 | $401.63 |
- Period change
- +13.85%
- Period low
- $352.79
- Period high
- $444.12
- Observations
- 64
- Updated
- Sep 24, 2026, 8:00 PM
About Amgen Inc
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Company websiteClassifications
- Biotechnology · Biotech
- Pharmaceuticals · Pharma
- Healthcare
Market details
- Type
- Company
- Market
- XNAS
- Operating market
- XNAS
- Country
- US
- Currency
- USD
- Market capitalization
- $212,554,879,085.80
- Employees
- 31.5K